Get started
Verona Pharma plc Sponsored ADRVerona Pharma plc Sponsored ADRVerona Pharma plc Sponsored ADR

Verona Pharma plc Sponsored ADR

No trades
See on Supercharts
OverviewFinancialsNewsDocumentsDiscussionsForecastSeasonals

I9SA fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
I9SA has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company